BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma
Abstract Background Adult patients with T‐cell lymphoblastic lymphoma (T‐LBL) are treated with high‐intensity chemotherapy regimens, but the response rate is still unsatisfactory because of frequent drug resistance. We aimed to investigate the potential mechanisms of drug resistance in adults with T...
Main Authors: | Xiao‐Peng Tian, Jun Cai, Shu‐Yun Ma, Yu Fang, Hui‐Qiang Huang, Tong‐Yu Lin, Hui‐Lan Rao, Mei Li, Zhong‐Jun Xia, Tie‐Bang Kang, Dan Xie, Qing‐Qing Cai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | https://doi.org/10.1002/cac2.12039 |
Similar Items
-
Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting
by: Thomas eKnight, et al.
Published: (2014-06-01) -
RasGRP1, but not RasGRP3, is required for efficient thymic β-selection and ERK activation downstream of CXCR4.
by: Dominic P Golec, et al.
Published: (2013-01-01) -
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
by: Shuiyan Wu, et al.
Published: (2021-04-01) -
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
by: Yanlin Song, et al.
Published: (2023-01-01) -
Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1
by: Jeffrey S Iwig, et al.
Published: (2013-07-01)